Total Payments
$8,200
2024 Payments
$993.14
Companies
34
Transactions
481
Medicare Patients
8,409
Medicare Billing
$896,999
Payment Breakdown by Category
Food & Beverage$8,109 (98.9%)
Education$91.39 (1.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,109 | 477 | 98.9% |
| Education | $91.39 | 4 | 1.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $2,907 | 217 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $1,409 | 71 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $1,177 | 70 | $0 (2024) |
| Circassia Pharmaceuticals Inc | $549.45 | 33 | $0 (2020) |
| Regeneron Healthcare Solutions, Inc. | $385.17 | 18 | $0 (2024) |
| Amgen Inc. | $195.78 | 2 | $0 (2019) |
| GENZYME CORPORATION | $181.65 | 10 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $176.45 | 2 | $0 (2023) |
| PFIZER INC. | $125.44 | 3 | $0 (2021) |
| Janssen Pharmaceuticals, Inc | $123.89 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $993.14 | 50 | GlaxoSmithKline, LLC. ($299.04) |
| 2023 | $994.67 | 54 | GlaxoSmithKline, LLC. ($337.01) |
| 2022 | $1,300 | 75 | GlaxoSmithKline, LLC. ($473.86) |
| 2021 | $928.35 | 64 | GlaxoSmithKline, LLC. ($353.33) |
| 2020 | $667.24 | 45 | GlaxoSmithKline, LLC. ($333.45) |
| 2019 | $1,015 | 70 | GlaxoSmithKline, LLC. ($409.06) |
| 2018 | $1,280 | 71 | GlaxoSmithKline, LLC. ($360.59) |
| 2017 | $1,022 | 52 | GlaxoSmithKline, LLC. ($340.95) |
All Payment Transactions
481 individual payment records from CMS Open Payments — Page 1 of 20
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $22.91 | General |
| Category: RESPIRATORY | ||||||
| 12/12/2024 | Exact Sciences Corporation | Cologuard Collection Kit (Device) | Food and Beverage | In-kind items and services | $14.90 | General |
| Category: Oncology | ||||||
| 12/11/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $17.06 | General |
| Category: PSYCHIATRY | ||||||
| 12/02/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $21.27 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/02/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $19.22 | General |
| Category: Respiratory | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $15.60 | General |
| Category: RESPIRATORY | ||||||
| 11/12/2024 | AstraZeneca Pharmaceuticals LP | AIRSUPRA (Drug) | Food and Beverage | In-kind items and services | $13.93 | General |
| Category: Respiratory | ||||||
| 11/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 11/06/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $6.23 | General |
| Category: IMMUNOLOGY | ||||||
| 11/04/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $15.78 | General |
| Category: RESPIRATORY | ||||||
| 10/29/2024 | AstraZeneca Pharmaceuticals LP | FASENRA (Biological) | Food and Beverage | In-kind items and services | $21.39 | General |
| Category: Respiratory | ||||||
| 10/28/2024 | Grifols USA, LLC | Prolastin-C Liquid (Biological) | Food and Beverage | In-kind items and services | $16.41 | General |
| Category: Pulmonology | ||||||
| 10/14/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: Immunology | ||||||
| 10/01/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $12.81 | General |
| Category: RESPIRATORY | ||||||
| 09/30/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.80 | General |
| Category: IMMUNOLOGY | ||||||
| 09/26/2024 | GlaxoSmithKline, LLC. | AREXVY (Drug), TRELEGY ELLIPTA | Food and Beverage | In-kind items and services | $26.52 | General |
| Category: RESPIRATORY | ||||||
| 09/23/2024 | Takeda Pharmaceuticals U.S.A., Inc. | GLASSIA (Biological) | Food and Beverage | In-kind items and services | $15.26 | General |
| Category: IMMUNOLOGY | ||||||
| 09/16/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.97 | General |
| 09/11/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $23.78 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 09/09/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $16.67 | General |
| Category: Immunology | ||||||
| 08/28/2024 | Philips North America LLC | (8874) inCourage (Device) | Food and Beverage | Cash or cash equivalent | $16.27 | General |
| Category: Medical Device | ||||||
| 08/26/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug) | Food and Beverage | In-kind items and services | $17.59 | General |
| Category: RESPIRATORY | ||||||
| 08/14/2024 | GlaxoSmithKline, LLC. | TRELEGY ELLIPTA (Drug), AREXVY | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: RESPIRATORY | ||||||
| 08/12/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | STIOLTO RESPIMAT (Drug), SPIRIVA RESPIMAT | Food and Beverage | In-kind items and services | $17.47 | General |
| Category: RESPIRATORY | ||||||
| 08/05/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $13.91 | General |
| Category: Immunology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 1,523 | 2,029 | $266,670 | $134,605 |
| 2022 | 13 | 1,870 | 2,607 | $340,035 | $171,815 |
| 2021 | 12 | 2,219 | 3,940 | $537,180 | $275,881 |
| 2020 | 15 | 2,797 | 4,940 | $585,755 | $314,698 |
Total Patients
8,409
Total Services
13,516
Medicare Billing
$896,999
Procedure Codes
53
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 350 | 669 | $100,850 | $64,341 | 63.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 163 | 237 | $27,255 | $15,364 | 56.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 96 | 96 | $24,000 | $12,050 | 50.2% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 94 | 170 | $21,250 | $10,744 | 50.6% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2023 | 221 | 224 | $23,380 | $9,138 | 39.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2023 | 222 | 225 | $23,320 | $8,671 | 37.2% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2023 | 222 | 225 | $25,000 | $6,024 | 24.1% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 19 | 19 | $3,230 | $2,014 | 62.3% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2023 | 20 | 26 | $2,800 | $1,724 | 61.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 12 | $4,200 | $1,688 | 40.2% |
| 94664 | Evaluation of use of breathing device | Office | 2023 | 68 | 87 | $4,350 | $1,171 | 26.9% |
| G0399 | Home sleep test (hst) with type iii portable monitor, unattended; minimum of 4 channels: 2 respiratory movement/airflow, 1 ecg/heart rate and 1 oxygen saturation | Office | 2023 | 15 | 15 | $4,875 | $1,028 | 21.1% |
| 94618 | Test for exercise-induced lung stress | Office | 2023 | 22 | 24 | $2,160 | $648.00 | 30.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 363 | 714 | $108,400 | $69,470 | 64.1% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 153 | 418 | $52,250 | $24,368 | 46.6% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 177 | 268 | $30,820 | $18,111 | 58.8% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 103 | 103 | $25,750 | $13,854 | 53.8% |
| 94729 | Test to examine how well the lungs exchange gases | Office | 2022 | 286 | 287 | $29,140 | $12,564 | 43.1% |
| 94726 | Test to determine lung volumes using sensors | Office | 2022 | 285 | 285 | $28,900 | $11,480 | 39.7% |
| 94060 | Test to measure expiratory airflow and volume changes before and after medication administration | Office | 2022 | 288 | 289 | $31,280 | $8,190 | 26.2% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 39 | 41 | $14,350 | $6,479 | 45.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 17 | 18 | $3,060 | $1,978 | 64.6% |
| 99442 | Telephone medical discussion with physician, 11-20 minutes | Office | 2022 | 24 | 26 | $2,775 | $1,837 | 66.2% |
| 94618 | Test for exercise-induced lung stress | Office | 2022 | 38 | 48 | $3,960 | $1,256 | 31.7% |
| 94664 | Evaluation of use of breathing device | Office | 2022 | 83 | 96 | $4,800 | $1,235 | 25.7% |
About Dr. Michael Laffer, D.O
Dr. Michael Laffer, D.O is a Pulmonary Disease healthcare provider based in Madison Heights, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 12/05/2005. The National Provider Identifier (NPI) number assigned to this provider is 1639153497.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Michael Laffer, D.O has received a total of $8,200 in payments from pharmaceutical and medical device companies, with $993.14 received in 2024. These payments were reported across 481 transactions from 34 companies. The most common payment nature is "Food and Beverage" ($8,109).
As a Medicare-enrolled provider, Laffer has provided services to 8,409 Medicare beneficiaries, totaling 13,516 services with total Medicare billing of $896,999. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Ad
Practice Information
- Specialty Pulmonary Disease
- Location Madison Heights, MI
- Active Since 12/05/2005
- Last Updated 02/16/2011
- Taxonomy Code 207RP1001X
- Entity Type Individual
- NPI Number 1639153497
Products in Payments
- TRELEGY ELLIPTA (Drug) $1,355
- STIOLTO RESPIMAT (Drug) $763.26
- NUCALA (Biological) $739.13
- DUPIXENT (Biological) $634.41
- BREZTRI (Drug) $518.22
- TUDORZA PRESSAIR (Drug) $465.18
- ANORO (Drug) $320.11
- BEVESPI AEROSPHERE (Drug) $256.03
- Prolia (Biological) $195.78
- AIRSUPRA (Drug) $183.39
- BREO (Drug) $168.51
- TEZSPIRE (Biological) $165.73
- INVOKANA (Drug) $123.89
- STIOLTO (Drug) $117.29
- SPIRIVA RESPIMAT (Drug) $116.25
- AREXVY (Drug) $106.96
- GLASSIA (Biological) $100.79
- SOLIQUA (Drug) $97.46
- CHANTIX (Drug) $90.88
- ANORO ELLIPTA (Drug) $82.84
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.